STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] uniQure N.V. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

uniQure N.V. (QURE) disclosed insider transactions by a director on a Form 4 dated 11/06/2025. The reporting person exercised stock options for 15,840 ordinary shares at an exercise price of $4.57 (code M), then reported two open-market sales (code S): 15,840 shares at a weighted average price of $27.22 and 15,594 shares at $27.30. Following these transactions, 40,145 shares were beneficially owned directly.

The transactions were effected under a Rule 10b5-1 plan adopted on July 8, 2025. The filing notes footnote adjustments to prior reported holdings, and states the first sale’s weighted average reflects multiple trades between $27.00 and $27.38. The option covered 15,840 underlying shares, vested in full on June 19, 2025, and carries an expiration date of 06/19/2034.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gut Robert

(Last) (First) (Middle)
C/O UNIQURE N.V.
PAASHEUVELWEG 25A

(Street)
AMSTERDAM P7 11058BP

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
uniQure N.V. [ QURE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 11/06/2025 M(1) 15,840 A $4.57 71,579(2) D
Ordinary Shares 11/06/2025 S(1) 15,840 D $27.22(3) 55,739 D
Ordinary Shares 11/06/2025 S(1) 15,594 D $27.3 40,145 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.57 11/06/2025 M(1) 15,840 (4) 06/19/2034 Ordinary Shares 15,840 $0 0 D
Explanation of Responses:
1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
2. Adjusted to reflect (i) the sale of 1,120 shares under the Reporting Person's 10b5-1 plan on June 23, 2020, which was inadvertently omitted from the Form 4 filed on June 24, 2020, and (ii) the correction to a typographical error in the number of shares sold by the Reporting Person on June 13, 2024 reported on the Form 4 filed on June 17, 2024. The Form 4 reported the sale of 3,504 shares but should have reported the sale of 3,524 shares.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.00 to $27.38. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The Stock Option vested in full on June 19, 2025.
/s/ Christian Klemt, Attorney-in-Fact 11/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did QURE’s director report on Form 4?

An option exercise for 15,840 shares at $4.57 and two sales: 15,840 shares at a weighted average $27.22 and 15,594 shares at $27.30.

How many QURE shares does the reporting person own after the trades?

The filing shows 40,145 shares beneficially owned directly after the reported transactions.

Was a Rule 10b5-1 trading plan used for these transactions?

Yes. The transactions were made under a Rule 10b5-1 plan adopted on July 8, 2025.

What were the price details of the share sales?

One sale used a weighted average price of $27.22, with individual trades ranging from $27.00 to $27.38; another sale was at $27.30.

What are the key terms of the exercised option?

It covered 15,840 shares at an exercise price of $4.57, vested in full on June 19, 2025, and expires on 06/19/2034.

What is the insider’s relationship to uniQure (QURE)?

The reporting person is a Director of uniQure N.V.
Uniqure

NASDAQ:QURE

QURE Rankings

QURE Latest News

QURE Latest SEC Filings

QURE Stock Data

1.88B
58.37M
6.08%
96.92%
16.51%
Biotechnology
Pharmaceutical Preparations
Link
Netherlands
AMSTERDAM